A Phase 1b Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, for the Prevention of Chemotherapy-induced Myelosuppression
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 35
- 试验地点
- 28
- 主要终点
- Phase 1b Part 2 NSCLC
研究概览
简要总结
This is a Phase 1b, multicenter, 2-part study of ALRN-6924 for the prevention of chemotherapy-induced side effects.
Part 1 SCLC is an open-label, multicenter study of ALRN-6924 for the prevention of chemotherapy-induced side effects in patients with p53-mutated ED SCLC undergoing 2nd-line treatment with topotecan. (Part 1 has completed enrollment).
Part 2 NSCLC is a randomized, double-blind, placebo-controlled, multicenter study of ALRN-6924 for the prevention of chemotherapy-induced side effects in patients with p53-mutated advanced NSCLC of adenocarcinoma histology receiving 1st-line treatment with carboplatin plus pemetrexed with or without immunotherapy.
详细描述
During Part 1 SCLC, topotecan will be administered per standard practice on Days 1-5 of 21-day cycles. Patients will be randomized to receive 1 of 2 initial ALRN-6924 dose levels, to be administered prior to each planned topotecan dose. The incidence, severity and duration of hematologic toxicities, including neutropenia, thrombocytopenia, and febrile neutropenia, will be determined. The safety and tolerability of each ALRN-6924 dose level will be assessed during Part 1. ALRN-6924 is given either 24 hr or 6 hr prior to each topotecan administration.
Part 2 NSCLC of the study will be conducted in two stages. In Stage 1, a total of 20 patients will be randomized 1:1 to receive (with or without immunotherapy) either carboplatin plus pemetrexed plus ALRN-6924 or carboplatin plus pemetrexed plus placebo.
During Stage 1 of Part 2 NSCLC, two interim analyses will be conducted after 10 and 20 patients, respectively, have been evaluated. The purpose of the two interim analyses is to confirm safety and exclude futility. In Stage 2 of Part 2 NSCLC, an additional 40 patients will be randomized to treatment as described for Stage 1.
Immunotherapy and/or bevacizumab may be used concurrently with chemotherapy and after completion of 1st-line treatment (i.e., for maintenance purposes) as per local standard of care. Time of administration of immunotherapy and/or bevacizumab relative to chemotherapy will follow local standards of care.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histopathological confirmation of Stage IV NSCLC of adenocarcinoma histology. Cytological diagnosis of NSCLC is acceptable if sufficient tumor tissue is available for p53 mutation analysis. FDA approved liquid biopsies are also acceptable.
- •Presence of one or more p53 mutations.
- •Measurable disease using RECIST 1.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status 0-
- •Adequate hematological status.
- •Adequate hepatic and renal function.
- •Phase 1b, Part 2 NSCLC
排除标准
- •Advanced NSCLC tumors with EGFR mutations or ALK re-arrangement or other actionable genetic aberrations for which an approved targeted treatment is available. Patients who received prior treatment with EGFR or ALK inhibitors or other systemic drugs or immunotherapy for NSCLC are not eligible.
- •Patients who are candidates for anti-PD-1 monotherapy in 1st line advanced NSCLC (e.g. tumors with high PD-L1 expression).
- •Presence of active central nervous system metastases and/or carcinomatous meningitis.
- •Significant weight loss (≥15% body weight) within the 4 weeks prior to enrollment.
- •Phase 1b, Part 1 SCLC Inclusion Criteria:
- •Histopathological confirmation of ED SCLC that has recurred or been refractory to one line of treatment with standard platinum-based chemotherapy or immuno-chemotherapy. Patients who received immunotherapy after platinum-based chemotherapy are eligible.
- •Presence of one or more p53 mutations.
- •Measurable disease using RECIST 1.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status 0-
- •Adequate hematological status.
- •Adequate hepatic and renal function.
- •Phase 1b, Part 1 SCLC Exclusion Criteria:
- •More than one line of prior chemotherapy for ED SCLC (prior immunotherapy is permitted, concurrent with or subsequent to first line chemotherapy).
- •Presence of active central nervous system metastases and/or carcinomatous meningitis.
- •Significant weight loss (≥15% body weight) within the 4 weeks prior to enrollment.
研究组 & 干预措施
Part 2 NSCLC: ALRN-6924+Carboplatin+Pemetrexed
干预措施: ALRN-6924 (Drug)
Part 2 NSCLC: ALRN-6924+Carboplatin+Pemetrexed
干预措施: Carboplatin (Drug)
Part 2 NSCLC: ALRN-6924+Carboplatin+Pemetrexed
干预措施: Pemetrexed (Drug)
Part 2 NSCLC: Placebo+Carboplatin+Pemetrexed
干预措施: Carboplatin (Drug)
Part 2 NSCLC: Placebo+Carboplatin+Pemetrexed
干预措施: Pemetrexed (Drug)
Part 2 NSCLC: Placebo+Carboplatin+Pemetrexed
干预措施: Placebo (Drug)
Part 1 SCLC: ALRN-6924+Topotecan
干预措施: ALRN-6924 (Drug)
Part 1 SCLC: ALRN-6924+Topotecan
干预措施: Topotecan (Drug)
结局指标
主要结局
Phase 1b Part 2 NSCLC
时间窗: Approximately 6 months
Proportion of completed treatment cycles that are free of Grade ≥ 3 hematological toxicities (including neutropenia, anemia, thrombocytopenia and febrile neutropenia), and free of chemotherapy dose reductions, and free of use of growth factors and transfusions.
Phase 1b Part 1 SCLC
时间窗: Approximately 19 months
Proportion of patients with National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade 3/4 treatment emergent adverse events (TEAEs)
次要结局
未报告次要终点